|
MechanismNEGF2 inhibitors |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingPhase 1 A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
100 Clinical Results associated with Rock BioMedical, Inc.
0 Patents (Medical) associated with Rock BioMedical, Inc.
100 Deals associated with Rock BioMedical, Inc.
100 Translational Medicine associated with Rock BioMedical, Inc.